📰 Expanded Use Access Program News
Expanded Use Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Expanded Use Access Program. Real-time updates on events, politics, business and more.
April 1, 2024
Operator: Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
March 27, 2024
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded...
February 20, 2024
20.02.2024 - ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will enroll approximately 216 patients ... Seite 1
August 31, 2023
A team of University of Minnesota Medical School researchers successfully tested a new antifungal therapy to treat fungal meningitis. The trial results were published today in the peer-reviewed journal Clinical Infectious Diseases.
August 22, 2023
BEDMINSTER, N.J., Aug. 22, 2023 -- Matinas BioPharma , a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery...
August 9, 2023
FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...